There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC – Research Report) and CTI BioPharma (CTIC – Research Report) with bullish sentiments.
Revance Therapeutics (RVNC)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Revance Therapeutics today and set a price target of $42.00. The company’s shares closed last Monday at $31.47.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 10.0% and a 42.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Praxis Precision Medicines, and Crinetics Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $35.63 average price target.
See the top stocks recommended by analysts >>
CTI BioPharma (CTIC)
In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on CTI BioPharma, with a price target of $9.00. The company’s shares closed last Monday at $4.26.
According to TipRanks.com, Hazlett is a 2-star analyst with an average return of 0.2% and a 35.6% success rate. Hazlett covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Eiger Biopharmaceuticals, and Intra-Cellular Therapies.
CTI BioPharma has an analyst consensus of Strong Buy, with a price target consensus of $11.16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RVNC: